ATE245030T1 - Antigen-besierende heteropolymere zur behandlung von autoimmunkrankheiten mittels diesen - Google Patents

Antigen-besierende heteropolymere zur behandlung von autoimmunkrankheiten mittels diesen

Info

Publication number
ATE245030T1
ATE245030T1 AT95912577T AT95912577T ATE245030T1 AT E245030 T1 ATE245030 T1 AT E245030T1 AT 95912577 T AT95912577 T AT 95912577T AT 95912577 T AT95912577 T AT 95912577T AT E245030 T1 ATE245030 T1 AT E245030T1
Authority
AT
Austria
Prior art keywords
antigen
heteropolymers
autoimmune diseases
human
passing
Prior art date
Application number
AT95912577T
Other languages
English (en)
Inventor
Ronald P Taylor
Polly J Ferguson
Edward N Martin
William S Sutherland
Craig J Reist
Kirsten Greene
Cyd Johnson
Original Assignee
Univ Virginia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia filed Critical Univ Virginia
Application granted granted Critical
Publication of ATE245030T1 publication Critical patent/ATE245030T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT95912577T 1994-02-28 1995-02-28 Antigen-besierende heteropolymere zur behandlung von autoimmunkrankheiten mittels diesen ATE245030T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20257294A 1994-02-28 1994-02-28
PCT/US1995/002165 WO1995022977A1 (en) 1994-02-28 1995-02-28 Antigen-based heteropolymers and method for treating autoimmune diseases using the same

Publications (1)

Publication Number Publication Date
ATE245030T1 true ATE245030T1 (de) 2003-08-15

Family

ID=22750436

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95912577T ATE245030T1 (de) 1994-02-28 1995-02-28 Antigen-besierende heteropolymere zur behandlung von autoimmunkrankheiten mittels diesen

Country Status (11)

Country Link
US (2) US5879679A (de)
EP (1) EP0743856B1 (de)
JP (1) JPH09509572A (de)
AT (1) ATE245030T1 (de)
AU (1) AU696964B2 (de)
CA (1) CA2183535A1 (de)
DE (1) DE69531290T2 (de)
DK (1) DK0743856T3 (de)
ES (1) ES2207646T3 (de)
PT (1) PT743856E (de)
WO (1) WO1995022977A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU696964B2 (en) * 1994-02-28 1998-09-24 University Of Virginia Patent Foundation Antigen-based heteropolymers and method for treating autoimmune diseases using the same
CN1399562A (zh) * 1999-11-28 2003-02-26 拉卓拉药物公司 基于抗体亲和力来治疗狼疮的方法及使用这种方法的筛选方法和组合物
JP2004515233A (ja) * 2000-11-01 2004-05-27 イルーシス セラポーティクス，インコーポレーテッド タンパク質トランススプライシングによる二重特異性分子の作製方法
AU2002306728B2 (en) * 2001-03-15 2007-12-13 Elusys Therapeutics, Inc. Polyclonal populations of bispecific molecules and methods of production and uses thereof
WO2003007971A1 (en) * 2001-07-17 2003-01-30 University Of Virginia Patent Foundation Improved heteropolymer complexes and methods for their use
US20030114405A1 (en) * 2001-08-13 2003-06-19 Linnik Matthew D. Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function
US7378094B2 (en) * 2001-08-29 2008-05-27 University Of Virginia Patent Foundation Therapeutic uses of complement receptor 2
US7105135B2 (en) * 2001-10-16 2006-09-12 Lockheed Martin Corporation System and method for large scale detection of hazardous materials in the mail or in other objects
CA2485755A1 (en) * 2002-05-13 2003-11-20 Elusys Therapeutics, Inc. Purified composition of bispecific molecules and methods of production
CA2495047A1 (en) * 2002-06-13 2003-12-24 Cygene, Inc. Methods and compositions for in vivo clearance of pathogens
AU2003295330A1 (en) * 2002-09-16 2004-05-04 Elusys Therapeutics, Inc. Bispecific molecule comprising an anti-cr1 antibody cross-linked to an antigen-binding antibody fragment
WO2004060320A2 (en) * 2002-12-27 2004-07-22 La Jolla Pharmaceutical Company Methods of improving health-related quality of life in individuals with systemic lupus erythematosus
US20050031625A1 (en) * 2003-03-28 2005-02-10 Elusys Therapeutics, Inc. Methods and compositions for conversion of antibody activity
WO2004089422A2 (en) * 2003-03-30 2004-10-21 La Jolla Pharmaceutical Co. Methods of treating and monitoring systemic lupus erythematosus in individuals
WO2005005479A1 (en) 2003-05-09 2005-01-20 University Of Massachusetts Non-human animals expressing heterologous complement receptor type 1 (cr1) molecules on erythrocytes and uses therefor
WO2005116071A2 (en) * 2004-05-28 2005-12-08 University Of Massachusetts Snares for pathogenic or infectious agents and uses related thereto
US20060263792A1 (en) * 2004-10-29 2006-11-23 Elusys Therapeutics, Inc. Use of CR1-binding molecules in clearance and induction of immune responses
ZA200804082B (en) 2005-11-07 2010-02-24 Scripps Research Inst Compositions and methods for controlling tissue factor signaling specificity
US8828077B2 (en) * 2006-03-15 2014-09-09 Medinol Ltd. Flat process of preparing drug eluting stents
JP6017422B2 (ja) 2010-08-10 2016-11-02 エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）Ｅｃｏｌｅ Ｐｏｌｙｔｅｃｈｎｉｑｕｅ Ｆｅｄｅｒａｌｅ ｄｅ Ｌａｕｓａｎｎｅ （ＥＰＦＬ） 赤血球結合療法
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
FR2968304B1 (fr) * 2010-12-01 2014-03-14 Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic Nouveaux epaississants cationiques, exempts d'huile et de tensioactifs, procede pour leur preparation et composition en contenant.
NZ722352A (en) * 2012-02-15 2022-05-27 Ecole Polytechnique Fed Lausanne Epfl Erythrocyte-binding therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
KR20240154672A (ko) 2014-02-21 2024-10-25 에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘) 글리코타겟팅 치료제
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
EP3638296A1 (de) 2017-06-16 2020-04-22 The University Of Chicago Zusammensetzungen und verfahren zur herbeiführung einer immuntoleranz
WO2019075523A1 (en) * 2017-10-20 2019-04-25 Csl Ltd. PROCESS
SG11202011078VA (en) 2018-05-09 2020-12-30 Univ Chicago Compositions and methods concerning immune tolerance
EP4574842A1 (de) * 2023-12-22 2025-06-25 Deutsches Rheuma-Forschungszentrum Berlin Bispezifisches konjugat für antigenspezifische b-zelldepletion durch t-zellen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005801A1 (en) * 1990-10-04 1992-04-16 University Of Virginia Alumni Patents Foundation Primate erythrocyte bound monoclonal antibody heteropolymers
AU696964B2 (en) * 1994-02-28 1998-09-24 University Of Virginia Patent Foundation Antigen-based heteropolymers and method for treating autoimmune diseases using the same

Also Published As

Publication number Publication date
EP0743856A4 (de) 2000-04-12
US5879679A (en) 1999-03-09
WO1995022977A1 (en) 1995-08-31
AU696964B2 (en) 1998-09-24
US20020103343A1 (en) 2002-08-01
EP0743856A1 (de) 1996-11-27
AU1967795A (en) 1995-09-11
DE69531290T2 (de) 2004-05-13
ES2207646T3 (es) 2004-06-01
EP0743856B1 (de) 2003-07-16
DK0743856T3 (da) 2003-11-10
JPH09509572A (ja) 1997-09-30
DE69531290D1 (de) 2003-08-21
CA2183535A1 (en) 1995-08-31
PT743856E (pt) 2003-12-31

Similar Documents

Publication Publication Date Title
DE69531290D1 (de) Antigen-besierende heteropolymere zur behandlung von autoimmunkrankheiten mittels diesen
DE69531679D1 (de) Für e-selectin und p-selectin spezifische kreuzreaktive monoklonale antikörper
ATE347565T1 (de) Bispezifischer antikörper zur effektiven behandlung von b-zell lymphomen und zellinien
ES2084338T3 (es) Anticuerpos recombinantes especificos para el tnf alfa.
ATE403680T1 (de) Herstellung tetravalenter antikörper
NO963168D0 (no) Immunstimulatoriske monoklonale antistoffer
DK1194167T3 (da) Immunoterapi af autoimmune sygdomme under anvendelse af B-cellespecifikke antistoffer
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
ATE132197T1 (de) Monoklonale antikörper
DE69316948D1 (de) Lösliche Liganden für CD40
NO883306D0 (no) Farmasoeytisk aktive konjugater med forbedret bindingsspesifisitet for kroppsvev.
ATE433998T1 (de) Divalent anti-t-zellen immuntoxinen und deren verwendung
ATE205532T1 (de) Zellzyklus-unabhängige, gliomaoberflach- spezifische, menschliche monoklonale antikörper
NO973875D0 (no) Fremgangsmåte for simulering av en immunrespons
PT954333E (pt) Receptores soluveis de linfotoxina-beta, anticorpos de receptores de anti-linfotoxina e anticorpos de ligandos de anti-linfotoxina como agentes terapeuticos para o tratamento de doencas imunologicas
ATE484294T1 (de) Anti-interleukin-9 antikörper oder anti- interleukin-9 rezeptor antikörper zur behandlung von bronchialem hyperreaktionsvermögen
ATE251886T1 (de) Verwendunf von apoe zum binden von tau und map2c proteinen und zur behandlung von alzheimer's krankheit
DK0749481T3 (da) Humaniserede monoklonale antistoffer mod human interleukin-4
DE69615843D1 (de) Il-8 antagonisten zur behandlung von asthma
SE8800886D0 (sv) Immunoglobulin conjugates
ATE100331T1 (de) Verfahren zur behandlung von septischem schock.
KR910006478A (ko) 인체 트립타제 유사 단백질
EP0959899A4 (de) LO-CD2a Antikörper und deren Verwendung zur Hemmung der T-zellen Aktivierung und Proliferation

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0743856

Country of ref document: EP

REN Ceased due to non-payment of the annual fee